Thromboembolic Events Associated with Thalidomide and Multimodality Therapy for Soft Tissue Sarcomas: Results of RTOG 0330

Table 2

Nonthromboembolic adverse events for cohort A and B patients in RTOG 0330.

	Cohort A (𝑛=15) Grade					Cohort B (𝑛=7) Grade
Adverse event	1	2	3	4	5	1	2	3	4	5
Auditory/ear	0	1	0	0	0	0	0	0	0	0
Blood/bone marrow	2	1	5	5	0	2	0	0	0	0
Cardiac arrhythmia	1	2	1	0	0	0	1	0	0	0
Cardiac general	1	3	0	0	0	1	0	0	0	0
Coagulation	0	0	0	0	0	1	0	0	0	0
Constitutional symptoms	3	8	3	0	0	1	3	0	0	0
Dermatology/skin	2	7	2	0	0	1	3	1	0	0
Endocrine	1	0	0	0	0	0	0	0	0	0
Gastrointestinal	2	8	3	0	0	3	1	0	0	0
Hemorrhage/bleeding	1	1	0	0	0	1	1	0	0	0
Infection	0	2	2	0	0	0	1	2	0	0
Lymphatics	5	1	0	0	0	1	0	0	0	0
Metabolic/laboratory	3	5	2	0	0	1	1	0	0	0
Musculoskeletal/soft tissue	0	4	0	0	0	0	1	2	0	0
Neurology	2	4	3	0	0	0	4	0	0	0
Ocular/visual	3	0	0	0	0	0	1	0	0	0
Pain	2	8	0	0	0	1	1	0	0	0
Pending	1	0	1	1	0	0	0	0	0	0
Pulmonary/upper respiratory	0	2	0	0	0	0	0	0	0	0
Sexual/reproductive function	0	1	0	0	0	0	0	0	0	0
Worst nonhematologic	1	5	7	1	0	1	2	4	0	0
(%)	(6.7)	(33.3)	(46.7)	(6.7)	(0.0)	(14.3)	(28.6)	(57.1)	(0.0)	(0.0)
Worst overall	1	2	6	6	0	1	2	4	0	0
(%)	(6.7)	(13.3)	(40.0)	(40.0)	(0.0)	(14.3)	(28.6)	(57.1)	(0.0)	(0.0)